Trazodone in Geriatric Patients (65+): Transition to Adult Care Guide

What Is Trazodone and Why Does Age Change Everything?

Trazodone blocks serotonin 5-HT2A and 5-HT2C receptors and inhibits serotonin reuptake at therapeutic doses. At the lower doses used for insomnia (25 to 100 mg), the sedating histamine H1 and alpha-1-adrenergic antagonism dominate. This pharmacodynamic profile does not change with age, but pharmacokinetics shift substantially after 65. Hepatic CYP3A4 activity declines by an estimated 20 to 30% with normal aging, and albumin levels fall, increasing the free fraction of this highly protein-bound drug (approximately 89 to 95% bound) [1].

The result: the same milligram dose produces higher peak plasma concentrations in older adults. A 50 mg nighttime dose in a 70-year-old may produce exposures equivalent to 75 to 90 mg in a 35-year-old, depending on body composition and liver function.

Pharmacokinetic Changes That Drive Dose Reduction

Renal clearance is a secondary route for trazodone metabolites. The American Geriatrics Society notes that GFR declines by roughly 1 mL/min/1.73 m² per year after age 40, meaning a 70-year-old patient may have a GFR 30% below young-adult norms even with a serum creatinine in the reference range [2]. Prescribers transitioning a patient from a younger-adult care team should not assume the prior dose was appropriate for the patient's current renal and hepatic status.

Pharmacodynamic Sensitivity in the Aging Brain

Age-related loss of dopaminergic and noradrenergic neurons increases sensitivity to alpha-1 blockade. Blood pressure autoregulation is less responsive, making a modest drop in peripheral resistance much more clinically significant. A 2019 retrospective analysis published in the Journal of the American Geriatrics Society found that trazodone was associated with a 1.7-fold increased odds of injurious falls in community-dwelling adults 65 and older (95% CI 1.3 to 2.3) [3].

Beers Criteria and Guideline Positioning

The American Geriatrics Society 2023 Beers Criteria lists trazodone with a "use with caution" recommendation specifically citing orthostatic hypotension and CNS adverse effects in older adults [4]. The Criteria states: "Quality of evidence is low; strength of recommendation is strong." This is a nuanced designation. Trazodone does not carry the same "avoid" label as benzodiazepines or first-generation antihistamines, but it requires active monitoring rather than passive continuation.

What the Beers Criteria Does and Does Not Say

Clinicians sometimes misread the "use with caution" category as permission to continue any dose without adjustment. The 2023 document is explicit that lower starting doses, orthostatic blood pressure checks, and fall-risk assessment are expected steps, not optional ones [4]. A transitioning patient arriving with a 150 mg nightly dose from a younger-adult prescriber needs immediate re-evaluation.

The STOPP/START criteria (version 3, 2023), a European guideline complementary to Beers, identifies trazodone as appropriate in older adults with depression or insomnia when non-pharmacological options have failed, but specifically flags co-prescription with other serotonergic agents or hypnotics as a trigger for review [5].

Off-Label Insomnia Use: A Particular Concern at Transition

Trazodone is the most commonly prescribed non-benzodiazepine sedative-hypnotic in U.S. Adults, with an estimated 7.4 million prescriptions in 2023 [6]. The majority of these are off-label. Older adults transitioning from younger-adult care are frequently on trazodone for insomnia started in their 40s or 50s, a practice that may not have been re-evaluated for years. The FDA-approved label for trazodone does not include insomnia as an indication, and the label explicitly notes that controlled studies in elderly populations are limited [7].

Dosing at Transition: How to Reset the Prescription

The standard young-adult starting dose for trazodone in depression is 150 mg/day in divided doses, titrated up to 400 mg/day outpatient. Geriatric guidelines recommend a ceiling of 300 mg/day with a starting dose of 25 to 50 mg at bedtime for insomnia or 75 to 100 mg/day for depression [8].

Transition Dosing Protocol

When a patient 65 or older arrives from a younger-adult care team on a dose above these thresholds, the following sequence is appropriate:

1. Obtain an orthostatic blood pressure measurement at the first transition visit. A drop of 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing constitutes orthostatic hypotension per the American Autonomic Society definition [9].
2. Review the complete medication list for CYP3A4 inhibitors (fluconazole, clarithromycin, diltiazem) that raise trazodone plasma levels, and for CYP3A4 inducers (rifampin, carbamazepine) that lower them [7].
3. If the current dose exceeds 100 mg for insomnia or 200 mg for depression in a patient with documented orthostatic hypotension or falls, reduce by 25 to 50 mg immediately and schedule a 1-week follow-up.
4. Document the clinical rationale in the chart. Failure to dose-adjust in the presence of a known fall or orthostatic hypotension event creates medicolegal exposure.

Body Weight, Frailty, and Dose Calibration

Frail older adults (Clinical Frailty Scale score 5 to 7) have further reduced volume of distribution and slower drug clearance [10]. A frail 68 kg woman differs pharmacokinetically from a strong 68 kg woman of the same age. The Cockcroft-Gault equation using actual body weight remains the standard for estimating creatinine clearance and guiding dose adjustment in this population [2].

The HealthRX Geriatric Trazodone Transition Framework uses three tiers based on frailty score and current dose: (Tier 1) dose at or below guideline ceiling with no falls history, continue with monitoring; (Tier 2) dose above ceiling or single fall in past 12 months, reduce by 25% and recheck orthostatics at 1 week; (Tier 3) dose above ceiling plus recurrent falls or orthostatic hypotension documented, taper to discontinuation unless depression is the primary indication and alternatives have failed.

Drug Interactions That Emerge at Transition

Older adults carry an average of 5.6 prescription medications, a number that rises with age and comorbidity burden [11]. Trazodone interacts with several drug classes common in geriatric populations.

CNS Depressants

The most dangerous interaction at transition is additive CNS depression. Benzodiazepines, non-benzodiazepine hypnotics (zolpidem, eszopiclone), opioids, and gabapentinoids all potentiate trazodone sedation. A 2020 JAMA Internal Medicine analysis of Medicare Part D data found that 22.4% of older adults dispensed a sedating antidepressant also received a concurrent opioid prescription [12]. Prescribers should flag this combination for immediate reconciliation.

Serotonin Syndrome Risk

Trazodone combined with other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid, methylene blue) raises serotonin syndrome risk. The Hunter Serotonin Toxicity Criteria define the syndrome by clonus, agitation, diaphoresis, tremor, and hyperreflexia, and older adults may present atypically with confusion as the dominant symptom [13]. At transition, any patient on trazodone plus an SSRI requires explicit documentation that the combination was intentional and the patient has been counseled.

Cardiovascular Drug Interactions

Trazodone prolongs the QTc interval modestly. Co-administration with other QT-prolonging drugs (amiodarone, haloperidol, fluoroquinolones, azithromycin) requires a baseline ECG. The FDA label states that trazodone should be used with caution in patients with cardiac disease, and the prescribing clinician at transition should confirm whether a baseline ECG was obtained in the previous care setting [7].

Alpha-blockers used for benign prostatic hyperplasia (tamsulosin, terazosin) add to trazodone's alpha-1 blocking effect and substantially worsen orthostatic hypotension risk. This combination is common in older men and is frequently overlooked at care transitions.

Fall Risk: Assessment and Mitigation

Falls are the leading cause of injury death in U.S. Adults 65 and older, accounting for 36,000 deaths annually [14]. Psychotropic medications including sedating antidepressants are among the most modifiable fall risk factors.

Validated Screening Tools to Use at Transition

The Centers for Disease Control and Prevention STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm recommends asking three questions at every geriatric visit: Have you fallen in the past year? Do you feel unsteady? Are you afraid of falling? A "yes" to any one question triggers a Timed Up and Go (TUG) test [14]. A TUG time above 12 seconds is associated with elevated fall risk and should prompt medication review, including trazodone dose assessment.

The FRAX tool estimates 10-year fracture probability and can help frame the urgency of fall-risk reduction for patients who may resist medication changes [15].

Modifiable vs. Non-Modifiable Risk Factors

Trazodone dose is a modifiable risk factor. Vision impairment, peripheral neuropathy, and osteoporosis are not modifiable through prescription changes, which means the threshold for reducing trazodone should be lower in patients who already carry multiple non-modifiable risks. A 72-year-old woman with osteoporosis (T-score below -2.5), peripheral neuropathy from type 2 diabetes, and moderate vision impairment should be considered for trazodone tapering even if her dose is within the geriatric guideline ceiling, because her baseline fracture risk leaves no margin for additional pharmacological impairment of balance.

Sleep Alternatives When Trazodone Is Deprescribed

When trazodone is tapered for insomnia in older adults, the clinical gap requires a replacement plan. The American Academy of Sleep Medicine recommends cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in all adults, including those 65 and older [16]. A meta-analysis published in the Annals of Internal Medicine (N=2,102 participants, 20 trials) found CBT-I superior to pharmacotherapy at 6-month follow-up for sleep onset latency and sleep efficiency [17].

Non-Pharmacological Options

CBT-I components include sleep restriction therapy, stimulus control, relaxation techniques, and sleep hygiene education. The digital CBT-I program Sleepio showed statistically significant improvements in insomnia severity index scores (mean reduction 7.0 points vs. 3.5 placebo, P<0.001) in a randomized controlled trial of 1,711 adults [18].

Sleep hygiene education alone is not sufficient. Prescribers who simply tell a patient to "improve sleep hygiene" while tapering trazodone without a structured CBT-I referral are likely to see rebound insomnia and pressure to restart the drug.

Low-Risk Pharmacological Alternatives

If pharmacotherapy is needed after trazodone tapering, the Beers Criteria and American Geriatrics Society guidance support low-dose doxepin (3 to 6 mg) as an option with less orthostatic hypotension than trazodone, and melatonin (0.5 to 5 mg immediate release) for circadian-phase insomnia [4]. Suvorexant (Belsomra), an orexin receptor antagonist, carries FDA approval for insomnia and has a more favorable fall-risk profile than trazodone in preliminary geriatric studies, though head-to-head data remain limited [19].

Deprescribing Trazodone: A Step-by-Step Approach

Abrupt discontinuation of trazodone after prolonged use causes rebound insomnia and, in patients with depression, risks relapse. A structured taper is the standard approach.

Taper Protocols by Indication

For insomnia (doses typically 25 to 100 mg): reduce by 25 mg every 2 weeks. Most patients complete the taper in 4 to 8 weeks without significant withdrawal symptoms [20].

For depression (doses typically 150 to 300 mg): reduce by 25 to 50 mg every 2 weeks, with psychiatric co-management if the patient has a history of moderate-to-severe MDD. The 2024 Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines recommend involving the original prescribing clinician in any antidepressant taper lasting more than 6 months [21].

Monitoring During Taper

Schedule a phone or video check at 2 weeks after each dose reduction. Ask directly about rebound insomnia, mood changes, irritability, and somatic symptoms (nausea, dizziness). Document each check. A patient who reports three or more nights of severe insomnia after a dose reduction may need a slower schedule (reduce by 12.5 mg every 2 weeks using pill-splitting or a liquid formulation if available).

Monitoring Schedule After Transition

A newly transitioned geriatric patient on trazodone requires a structured monitoring calendar, not a "follow up in 3 months" instruction.

Recommended Visit and Test Schedule

Week 1 post-transition: orthostatic BP in office or via telehealth-directed home measurement. Review full medication list for interactions identified during transition reconciliation [2].

Week 4: reassess fall history, TUG test if initial screen was positive, and document current trazodone dose vs. Geriatric guideline ceiling. Confirm whether CBT-I has been initiated if insomnia was the indication.

Month 3: full medication reconciliation including any medications added by other specialists since transition. Repeat orthostatic BP. Assess whether depression or insomnia has responded and document whether continued trazodone use is still clinically justified.

Month 6 and annually: re-evaluate the need for ongoing trazodone. A patient stable on trazodone for insomnia who has completed CBT-I and achieved adequate sleep may be a candidate for a trial taper at this visit [16].

A 2022 systematic review in BMJ Open found that structured pharmacist-led medication review at care transitions reduced potentially inappropriate medication use in older adults by 30.4% compared to usual care (OR 0.69, 95% CI 0.55 to 0.87) [22]. Involving a clinical pharmacist in the transition visit is a direct, evidence-supported way to catch trazodone dose problems before they become adverse events.